GLP-1
Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (7–36) amide and GLP-1 (7–37). Active GLP-1 protein secondary structure includes two α-helices from amino acid position 13–20 and 24–35 separated by a linker region.
Beyond's analysis on GLP-1
- — Menu-Order AI appoints medical advisor to strengthen clinical credibility for its GLP-1-focused dietary AI platform
- — Oral semaglutide trial shows fewer heavy drinking days, pointing to a potential new indication for Alcohol Use Disorder
- — GLP-1 weight-loss drugs face scrutiny over reported side‑effects like ‘Ozempic face’ and hair loss
- — Cathie Wood’s Ark Invest is increasing its stake in a GLP-1 pharmaceutical stock that has appreciated 1,600% over the last decade
- — The focus on GLP-1 stocks indicates changing market sentiment beyond traditional drug manufacturers
- — The rising demand for high-protein whey amidst a significant shortage highlights critical shifts in the wellness industry
- — Increased adoption of weight-loss drugs leads to substantial savings on grocery expenses for households
Recent news mentioning GLP-1
- — GLP-1 Use Among Young Children With Obesity in US Remains Rare but Is Rising Rapidly
- — MasterClass Launches Understanding GLP-1s and Weight Loss, the Guidance That Should Come With Every GLP-1 Prescription¹
- — Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
- — New Survey: Consumers Using GLP-1 Medications Are Rethinking What Makes a Meal Worthwhile
- — Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
- — Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
- — Riverwater Sees a Market Overreaction in Stevanato Group (STVN) After Oral GLP-1 Launches
- — Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs
- — Victoria's Secret stock soars nearly 300% as GLP-1 weight-loss drugs help reshape lingerie buying habits
- — Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- — Meant Earns LegitScript Certification for Its Online GLP-1 Weight Care Platform
- — GLP-1 Coverage Fell From 72% to 60%. Is Eli Lilly’s Weight-Loss Boom Hitting an Insurance Wall?